Floatz logo

Metformin

Malignant Ascites

University of ChicagoSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
89/ 100

Competitive context

13 Active assets in the Malignant Ascites cohort.

Asset / SponsorPhaseRating
Catumaxomab
Neovii Biotech
Phase 2/3BB
5,5'-DINITROSALICIL
Wuhan YZY Biopharma Co., Ltd.
Phase 3BB
Serplulimab
Second Affiliated Hospital of Soochow University
Phase 1/2CC
Molgramostim
Second Affiliated Hospital of Soochow University
Phase 1/2CC
t3011
West China Hospital
Phase 1CC

View all 14 →

Same molecule, other indications

Metformin is also rated in:

Metabolism and Nutrition DisorderDormant
A
Indicative ·
82 / 100
View asset →
prediabetes syndromeDormant
A
Indicative ·
81 / 100
View asset →
gestational diabetesDormant
A
Indicative ·
81 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →